Cullinan Therapeutics Inc.
Clinical trials sponsored by Cullinan Therapeutics Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing targeted cancer therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug CLN-978 tested for Sjogren's sufferers
Disease control Recruiting nowThis early-stage trial is testing a new drug called CLN-978 in 36 adults with active, moderate to severe Sjogren's disease. The main goal is to see if the drug is safe and tolerable, while also checking how it affects immune cells in the blood. Participants receive the drug as a …
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New lupus drug CLN-978 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for stubborn arthritis: experimental drug targets immune cells
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in about 37 people whose rheumatoid arthritis has not responded to standard treatments. The goal is to see if the drug is safe and can control the disease by reducing certain immune cells (B cells) that drive inflammation. Pa…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug CLN-049 aims to fight Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called CLN-049 in about 60 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. CLN-049 is designed to help the body's immune cells attack cancer cells. The main goals …
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC